OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SRRK
Scholar Rock Holding Corporation
There isn't enough reported data to score SRRK yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SRRK Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Weak | |
| Unavailable |
SRRK's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SRRK PE Valuation
SRRK has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SRRK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect SRRK's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SRRK on earnings quality, reporting a profit while its opponent remains loss making.
SRRK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.22 | -$0.05 |
| Q2 2026 | -$3.31 | -$0.38 |
| Q1 2026 | -$3.45 | -$0.90 |
| Q4 2025 | -$3.29 | -$0.82 |
| Q3 2025 | -$3.17 | -$0.82 |
| Q2 2025 | -$2.93 | -$0.71 |
| Q1 2025 | -$2.55 | -$0.46 |
| Q4 2024 | -$2.47 | -$0.48 |
SRRK lost $3.22 per share over the past year, about the same as its loss the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SRRK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SRRK on profitability, with a higher operating margin.
SRRK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2022 | $33.2M | +605% |
| Q4 2021 | $4M | +18% |
| Q3 2021 | $5.5M | +80% |
| Q2 2021 | $4.6M | +18% |
| Q1 2021 | $4.7M | -6.4% |
| Q4 2020 | $3.4M | -55% |
SRRK's revenue is growing: $570,000 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -18607% | N/A |
| Q1 2022 | -21% | +557 points |
| Q4 2021 | -873% | -114 points |
| Q3 2021 | -679% | +99 points |
| Q2 2021 | -659% | -160 points |
| Q1 2021 | -578% | -226 points |
| Q4 2020 | -760% | -597 points |
| Q3 2020 | -778% | N/A |
SRRK's operating margin was −18607% last quarter, down 17948 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SRRK on cash generation, producing positive trailing cash flow while its opponent burns cash.
SRRK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$81.9M | -$12.9M |
| Q2 2026 | -$70.3M | +$6.8M |
| Q1 2026 | -$82.2M | -$3.2M |
| Q4 2025 | -$75.5M | -$26M |
| Q3 2025 | -$69M | -$16.5M |
| Q2 2025 | -$77.2M | -$27.9M |
| Q1 2025 | -$78.9M | -$29.1M |
| Q4 2024 | -$49.5M | -$12.2M |
SRRK has burned cash in almost every quarter: −$310M over the past year, against −$275M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SRRK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +1.8M shares |
| 1 year | +16% | +18.6M shares |
| 3 years | +64% | +51.8M shares |
| 5 years | +262% | +95.8M shares |
| Available history | +381% | +105M shares |
SRRK has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SRRK Net Leverage
SRRK's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SRRK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 25.9 | Neutral |
SRRK's weekly RSI is 44 (neutral) and its Stochastic is 26 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SRRK PE vs Healthcare Sector
SRRK has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SRRK on trend strength, trading above more of its moving averages.
SRRK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.1 | 2.2% below |
| 20 week MA | $49.5 | 13% below |
| 50 week MA | $47.5 | 9.2% below |
| 100 week MA | $41.5 | 4.1% above |
| 200 week MA | $27.1 | 59% above |
SRRK has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 59% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SRRK on returns for 2026, with the stronger performance.
SRRK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.0 | $51.5 | +296% |
| 2021 | $51.5 | $25.4 | -51% |
| 2022 | $25.4 | $7.97 | -69% |
| 2023 | $7.97 | $18.8 | +136% |
| 2024 | $18.8 | $44.5 | +136% |
| 2025 | $44.5 | $45.7 | +2.7% |
| 2026 YTD | $45.7 | $43.2 | -5.5% |
SRRK's yearly returns have swung widely, from +296% in 2020 to −69% in 2022. It's down 5.5% so far in 2026.